On Monday, Monte Rosa Therapeutics Inc (NASDAQ: GLUE) was 4.50% up from the session before settling in for the closing price of $4.22. A 52-week range for GLUE has been $3.21 – $12.40.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
When this article was written, the company’s average yearly earnings per share was at -56.92%. With a float of $45.99 million, this company’s outstanding shares have now reached $61.51 million.
Let’s look at the performance matrix of the company that is accounted for 134 employees. In terms of profitability, gross margin is 94.77%, operating margin of -107.26%, and the pretax margin is -92.74%.
Monte Rosa Therapeutics Inc (GLUE) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Monte Rosa Therapeutics Inc stocks. The insider ownership of Monte Rosa Therapeutics Inc is 25.23%, while institutional ownership is 80.18%. The most recent insider transaction that took place on Mar 24 ’25, was worth 58,383. In this transaction Director of this company bought 10,000 shares at a rate of $5.84, taking the stock ownership to the 10,000 shares. Before that another transaction happened on Oct 28 ’24, when Company’s 10% Owner sold 89,990 for $9.66, making the entire transaction worth $869,240. This insider now owns 2,007,948 shares in total.
Monte Rosa Therapeutics Inc (GLUE) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -56.92% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -20.46% during the next five years compared to -41.09% drop over the previous five years of trading.
Monte Rosa Therapeutics Inc (NASDAQ: GLUE) Trading Performance Indicators
You can see what Monte Rosa Therapeutics Inc (GLUE) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 2.40. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.59. Likewise, its price to free cash flow for the trailing twelve months is 7.14.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.03, a number that is poised to hit -0.40 in the next quarter and is forecasted to reach -1.63 in one year’s time.
Technical Analysis of Monte Rosa Therapeutics Inc (GLUE)
Monte Rosa Therapeutics Inc (NASDAQ: GLUE) saw its 5-day average volume 1.34 million, a positive change from its year-to-date volume of 0.79 million. As of the previous 9 days, the stock’s Stochastic %D was 61.26%. Additionally, its Average True Range was 0.48.
During the past 100 days, Monte Rosa Therapeutics Inc’s (GLUE) raw stochastic average was set at 12.64%, which indicates a significant decrease from 37.14% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 75.05% in the past 14 days, which was lower than the 81.92% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.76, while its 200-day Moving Average is $6.10. Nevertheless, the first resistance level for the watch stands at $4.55 in the near term. At $4.70, the stock is likely to face the second major resistance level. The third major resistance level sits at $4.86. If the price goes on to break the first support level at $4.24, it is likely to go to the next support level at $4.08. The third support level lies at $3.93 if the price breaches the second support level.
Monte Rosa Therapeutics Inc (NASDAQ: GLUE) Key Stats
There are 61,510K outstanding shares of the company, which has a market capitalization of 271.26 million. As of now, sales total 75,620 K while income totals -72,700 K. Its latest quarter income was 60,650 K while its last quarter net income were 13,440 K.
